72eb75ba
2021-10-27
Ok
Cortexyme's Alzheimer's treatment fails to meet main goals in study
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":855930165,"tweetId":"855930165","gmtCreate":1635322775201,"gmtModify":1635322775273,"author":{"id":4092523560597200,"authorId":4092523560597200,"authorIdStr":"4092523560597200","name":"72eb75ba","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855930165","repostId":1123295835,"repostType":4,"repost":{"id":"1123295835","pubTimestamp":1635322546,"share":"https://www.laohu8.com/m/news/1123295835?lang=&edition=full","pubTime":"2021-10-27 16:15","market":"us","language":"en","title":"Cortexyme's Alzheimer's treatment fails to meet main goals in study","url":"https://stock-news.laohu8.com/highlight/detail?id=1123295835","media":"Reuters","summary":"Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet th","content":"<p>Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease in a study.</p>\n<p>The drug, atuzaginstat, is designed to target the P. gingivalis bacteria found in the brain of patients suffering from the memory robbing disease.</p>\n<p>The mid-to-late stage study tested 643 patients and did not meet statistical significance in its goals, according to two scales measuring disease progression.</p>\n<p>In a group of patients with the bacteria detected in their saliva, the drug showed 57% slowing of cognitive decline on a commonly used test but failed to show significant benefits on another scale, which is generally filled out by a patient's caregiver.</p>\n<p>However, Cortexyme said the pill led to a reduction in the bacteria, which was associated with some improved outcomes at the end of the treatment period under the study. It plans to report the data to regulators to determine the path forward for the drug.</p>\n<p>Alzheimer's treatments have come into focus since the U.S. health regulator approved Biogen's(BIIB.O)controversial drug Aduhelm in June. The drug is used to treat early stages of the disease.</p>\n<p>\"There's nothing that is approved for treating the really sick patients with mild-to-moderate disease, which is where we've shown an effect,\" said Cortexyme's chief medical officer Michael Detke.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cortexyme's Alzheimer's treatment fails to meet main goals in study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCortexyme's Alzheimer's treatment fails to meet main goals in study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 16:15 GMT+8 <a href=https://www.reuters.com/business/healthcare-pharmaceuticals/cortexymes-alzheimers-treatment-fails-meet-main-goals-study-2021-10-26/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/cortexymes-alzheimers-treatment-fails-meet-main-goals-study-2021-10-26/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/cortexymes-alzheimers-treatment-fails-meet-main-goals-study-2021-10-26/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123295835","content_text":"Oct 26 (Reuters) - Cortexyme Inc(CRTX.O)said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease in a study.\nThe drug, atuzaginstat, is designed to target the P. gingivalis bacteria found in the brain of patients suffering from the memory robbing disease.\nThe mid-to-late stage study tested 643 patients and did not meet statistical significance in its goals, according to two scales measuring disease progression.\nIn a group of patients with the bacteria detected in their saliva, the drug showed 57% slowing of cognitive decline on a commonly used test but failed to show significant benefits on another scale, which is generally filled out by a patient's caregiver.\nHowever, Cortexyme said the pill led to a reduction in the bacteria, which was associated with some improved outcomes at the end of the treatment period under the study. It plans to report the data to regulators to determine the path forward for the drug.\nAlzheimer's treatments have come into focus since the U.S. health regulator approved Biogen's(BIIB.O)controversial drug Aduhelm in June. The drug is used to treat early stages of the disease.\n\"There's nothing that is approved for treating the really sick patients with mild-to-moderate disease, which is where we've shown an effect,\" said Cortexyme's chief medical officer Michael Detke.","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/855930165"}
精彩评论